ClinicalTrials.gg
RecruitingNCT06126224Updated Oct 16, 2026

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

A Phase 3 interventional study of KarXT and Placebo in Psychosis Associated With Alzheimer's Disease, sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company. Recruiting at 157 sites in 14 countries. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 2 months later.
Updated Oct 16, 2026Site recruiting status changed3 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
55 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing xanomeline in Alzheimer Disease — 10 open to participants now, 10 under way, 10 of them phase 3. xanomeline · Alzheimer Disease.

Planned enrollment
5th of 10
500 · median 463
Started
2023
with 1 other
Phase 3
10 of 10
10 open now
Registered
3rd of 10
by date
Lead sponsor
4 of 10
Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Among the 10 studies testing xanomeline in Alzheimer Disease, this one is the 5th largest by planned enrollment, is one of 2 that started in 2023, is one of 10 in phase 3, and was the 3rd registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

10 of the 10 studies testing xanomeline in Alzheimer Disease are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About xanomeline

xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing xanomeline in Alzheimer Disease, or all of them as a file.
02

Study summary

This is a Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of KarXT in male and female subjects who are aged 55 to 90 years and have mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.

The primary objective of the study is to evaluate the efficacy of KarXT compared with placebo in the treatment of subjects with psychosis associated with AD as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score.

03

Conditions studied

  • Psychosis Associated With Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Is a male or female aged 55 to 90 years, inclusive, at Screening.
  2. Can understand the nature of the trial and protocol requirements and provide or assent before any study assessments are performed.
  3. Meets clinical criteria for Possible AD or Probable AD.
  4. Must have a magnetic resonance imaging (MRI) or computed tomography (CT) scan of the brain (completed within the past 5 years) taken during or subsequent to the onset of dementia to rule out other central nervous system (CNS) disease that could account for the dementia syndrome, e.g., major stroke, neoplasm, subdural hematoma. If not available, a non-contrast brain MRI or non-contrast head CT must be done during Screening.
  5. Living at the same home or residential assisted-living facility for a minimum of 6 weeks before Screening.
  6. Have an identified study partner who should have daily contact (approximately 10 hours a week or more).
  7. History of psychotic symptoms (meeting International Psychogeriatric Association criteria) (Cummings 2020) for at least 2 months prior to Screening.
  8. CGI-S scale with a score ≥ 4 at Screening and Baseline.
  9. AD subjects are required to have NPI-C: Hallucinations and Delusions (H+D) score of ≥ 6 AND meet at least 1 of the following criteria at Screening and Baseline:

    1. Moderate to severe delusions, defined as NPI-C: Delusions domain score of ≥ 2 on 2 of the 8 items OR
    2. Moderate to severe hallucinations, defined as NPI-C: Hallucinations domain score of ≥ 2 on 2 of the 7 items
  10. score of 8 to 22, inclusive, at Screening.

Key Exclusion Criteria:

  1. Psychotic symptoms that are primarily attributable to a condition other than the AD causing the dementia.
  2. History of major depressive episode with psychotic features during the 12 months prior to Screening.
  3. History of bipolar disorder, schizophrenia, or schizoaffective disorder.
  4. Significant or severe medical conditions including pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, cardiovascular, or oncologic disease or any other condition that, in the opinion of the Investigator, could jeopardize the safety of the subject, ability to complete or comply with the study procedures or validity of the study results.
  5. History or high risk of urinary retention, gastric retention, or narrow-angle glaucoma as evaluated by the Investigator.
  6. Prior exposure to KarXT.
  7. History of to KarXT or trospium chloride.
  8. Experienced any significant adverse events (AEs) due to trospium.
  9. Participation in another clinical study in which the subject received an experimental or drug within 3 months before Screening or has participated in more than 2 clinical studies in the 12 months prior to Screening.
  10. Other protocol-defined inclusion/exclusion criteria may apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    KarXT

    Xanomeline and Trospium Chloride Capsules

    Drug: KarXT

  • Placebo comparator
    Placebo

    Placebo capsules

    Drug: Placebo

Interventions

  • DrugKarXT

    Drug pages: Xanomeline · Trospium

    KarXT 20/2 mg (total daily dose \[TDD\] 60/6 mg) KarXT 30/3 mg (TDD 90/9 mg) KarXT 40/4 mg (TDD 120/12 mg) KarXT 50/5 mg (TDD 150/15 mg) KarXT 66.7/6.67 mg (TDD 200/20 mg)

  • DrugPlacebo

    Placebo capsules

06

What researchers measure

Primary outcomes

  1. Change from Baseline to End of Treatment in the Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions (NPI-C: H+D) score

    Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions scale includes 2 domains from the NPI-C scale, namely, hallucinations and delusions. These 2 domains include the following number of items to be rated by the clinician: Hallucinations, 7 items (maximum score = 21) and Delusions, 8 items (maximum score = 24). The maximum score for the NPI-C: H+D scale is 45. Higher scores on this scale indicate worse outcomes.

    Time frame: Baseline and end of Treatment (up to 14 Weeks)

Secondary outcomes

  1. Change from Baseline to End of Treatment in the Clinical Global Impressions-Severity (CGI-S) scale

    Clinical Global Impressions-Severity (CGI-S) requires the assessor to consider aspects of the psychosis (hallucinations and delusions) prior to providing a global assessment of severity. Higher scores on this scale indicate worse outcomes.

    Time frame: Baseline and end of Treatment (up to 14 Weeks)

  2. Change From Baseline to end of Treatment in NPI-C Core score: Hallucinations, Delusions, Agitation, and Aggression Domains

    Time frame: Baseline and end of Treatment (up to 14 Weeks)

  3. Change From Baseline to end of Treatment in NPI-C: Agitation score

    Time frame: Baseline and end of Treatment (up to 14 Weeks)

  4. Change From Baseline to end of Treatment in NPI-C Core score: Caregiver Distress scale (Hallucinations, Delusions, Agitation, and Aggression domains)

    Time frame: Baseline and end of Treatment (up to 14 Weeks)

  5. Responder Rate

    Responder rate is defined as NPI-C: H+D score ≥ 40% improvement

    Time frame: Baseline and end of Treatment (up to 14 Weeks)

07

Study locations

7 of 157 sites recruiting
  • Local Institution - 1116
    Chandler, Arizona 85286, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1044
    Phoenix, Arizona 85012-2836, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1104
    Anaheim, California 92805-5854, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1119
    Canoga Park, California 91303-1844, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1151
    Encino, California 91316, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1142
    Lancaster, California 93534-2839, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1117
    Los Alamitos, California 90720-6506, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1103
    Sherman Oaks, California 91403-2131, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1007
    Walnut Creek, California 94596, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1160
    Apopka, Florida 32703-5835, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 1156
    Clermont, Florida 34711-5190, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1138
    Cutler Bay, Florida 33189-1230, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1162
    Delray Beach, Florida 33445-2581, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1164
    Doral, Florida 33122-1620, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1165
    Fort Myers, Florida 33912-4302, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1155
    Hialeah, Florida 33012-3158, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1107
    Hialeah, Florida 33012-3618, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1120
    Hialeah, Florida 33012-4648, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1140
    Hialeah, Florida 33016-1814, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0150
    Homestead, Florida 33032-8187, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1145
    Homestead, Florida 33032-8187, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1127
    Largo, Florida 33777-1359, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1039
    Maitland, Florida 32751-5669, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1146
    Maitland, Florida 32751-6138, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1159
    Miami, Florida 33032, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1118
    Miami, Florida 33122-1721, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1111
    Miami, Florida 33126-5683, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1108
    Miami, Florida 33133-4231, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1125
    Miami, Florida 33135-1601, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1115
    Miami, Florida 33135, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1143
    Miami, Florida 33145-2455, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1113
    Miami, Florida 33155-6630, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1009
    Miami, Florida 33155, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1129
    Miami, Florida 33165-3947, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1150
    Miami, Florida 33165, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1109
    Miami, Florida 33174-2950, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1158
    Miami, Florida 33175, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1147
    Miami, Florida 33176-7947, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1105
    Miami, Florida 33179-2537, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1157
    Miami, Florida 33184-1412, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1126
    Miami Gardens, Florida 33056-4000, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 1102
    Miami Lakes, Florida 33014-6435, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 1136
    Orlando, Florida 32806-1041, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1112
    Orlando, Florida 32807-3555, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1137
    Port Orange, Florida 32127-2914, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Health Synergy Clinical Research,LLC - Stuart
    Stuart, Florida 34994, United States
    Recruiting
    • Mohammad Nisar, Site 1101 · Contact786-831-7303
  • Local Institution - 1133
    Sweetwater, Florida 33182, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1041
    Tampa, Florida 33607-4629, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1124
    Tampa, Florida 33614-2700, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1123
    Tampa, Florida 33614-2869, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 1110
    Tampa, Florida 33629-5837, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1040
    The Villages, Florida 32159-8986, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 1131
    Viera, Florida 32940, United States
    Recruiting
    • Site 1131 · Contact
  • Local Institution - 1152
    Augusta, Georgia 30912-0020, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 1141
    Columbus, Georgia 31909-1693, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 1161
    Decatur, Georgia 30030, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1148
    Elgin, Illinois 60123-9215, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1114
    Marrero, Louisiana 70072-3083, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1139
    Rochester Hills, Michigan 48307-2760, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1132
    Flowood, Mississippi 39232, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1144
    Las Vegas, Nevada 89106-4145, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 1153
    New Hyde Park, New York 11042-2062, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 1135
    Port Jefferson Station, New York 11776-3386, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 1122
    Dayton, Ohio 45459-4248, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 1149
    Malvern, Pennsylvania 19355-3267, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 1106
    Cypress, Texas 77429-6070, United States
    Recruiting
    • Site 1106 · Contact
  • Local Institution - 1163
    Houston, Texas 77074-2085, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1154
    Katy, Texas 77450-1759, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1121
    Red Oak, Texas 75154, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 1134
    Stafford, Texas 77477-3929, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 2801
    Hasselt, Limburg 3500, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 2802
    Leuven, Vlaams Brabant 3000, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 2803
    Roeselare, West-Vlaanderen 8800, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1605
    Calgary, Alberta T2N 1N4, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 1603
    Hamilton, Ontario ON L8M 1W9, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 1602
    Toronto, Ontario M5B 1W8, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 1604
    Whitby, Ontario L1N 5S9, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 1606
    Montreal, Quebec H4H 1R3, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 1601
    Verdun, Quebec H4H 1R3, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 6005
    Las Condes, Santiago Metropolitan 7550000, Chile
    Not yet recruiting
    • Site 6005 · Contact
  • Biomedica Research Group
    Providencia, Santiago Metropolitan 7500000, Chile
    Recruiting
    • Sergio Gloger Kojchen, Site 6002 · Contact+56226758700
  • Psicomed Estudios Medicos
    Antofagasta, 1270244, Chile
    Recruiting
    • Luis Barra, Site 6003 · Contact+56552240334
  • Local Institution - 6001
    Las Condes, 7550000, Chile
    Recruiting
    • Site 6001 · Contact
  • Local Institution - 7007
    Hefei, Anhui 230022, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 7004
    Beijing, Beijing Municipality 100025, China
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 7045
    Beijing, Beijing Municipality 100070, China
    Not yet recruiting
    • Site 7045 · Contact
  • Local Institution - 7005
    Beijing, Beijing Municipality 100088, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 7015
    Chongqing, Chongqing Municipality 400016, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 7008
    Guangzhou, Guangdong 0, China
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 7016
    Guangzhou, Guangdong 510120, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 7009
    Guangzhou, Guangdong 510260, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 7003
    Shenzhen, Guangdong 518118, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 7014
    Nanjing, Jiangsu 210009, China
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 7013
    Nanjing, Jiangsu 210011, China
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 7012
    Nanchang, Jiangxi 330008, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 7001
    Shanghai, Shanghai Municipality 200030, China
    Completed

    Not enrolling at this site — choose another above.

  • Shanghai General Hospital - North Campus
    Shanghai, Shanghai Municipality 200080, China
    Recruiting
    • Yuncheng Wu, Site 7011 · Contact+861360172334
  • Local Institution - 7002
    Chengdu, Sichuan 610000, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 7043
    Zigong, Sichuan 643000, China
    Not yet recruiting
    • Site 7043 · Contact
  • Local Institution - 7019
    Tianjin, Tianjin Municipality 300222, China
    Completed

    Not enrolling at this site — choose another above.

Showing the first 100 of 157 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Dec 2026, 39 months after the start.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's planned 39 months is close to that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2023
First posted
Nov 13, 2023
StartActual
Aug 28, 2023
Primary completionEst.
Dec 9, 2026
CompletionEst.
Dec 9, 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added. Local Institution - 1122 is now Completed
Show 3 added (2 China, 1 Chile)
  • Local Institution - 6005 · Las Condes, Chile
  • Local Institution - 7045 · Beijing, China
  • Local Institution - 7043 · Zigong, China
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    3 sites added. Local Institution - 1122 is now Completed
    Show 3 added (2 China, 1 Chile)
    • Local Institution - 6005 · Las Condes, Chile
    • Local Institution - 7045 · Beijing, China
    • Local Institution - 7043 · Zigong, China
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06126224
Responsible party
Sponsor
First posted
Nov 13, 2023
Start date
Aug 28, 2023
Primary completion
Dec 9, 2026 (estimated)
Completion
Dec 9, 2026 (estimated)
Last update
Oct 16, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xanomeline · Trospium

Start the discussion